Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics' shares have experienced significant volatility over the past year, with a 52-week high of $7.51 and a 52-week low of $0.24. As of April 7, 2026, the share price was $6.75, a substantial increase from $0.25 on April 8, 2025. Key events include reporting Fourth Quarter and Full Year 2025 results, receiving $160 million in funding, and reporting positive 12-month Phase 2 interim data for NDV-01 in March 2026. The company participated in the Society of Urologic Oncology 26th Annual Meeting in December 2025 and held its Q3 2025 Financial Results Conference Call in November 2025. Relmada Therapeutics, Inc. dropped from the Russell Small Cap Comp Value Index in June 2025. Several analyst ratings and price target adjustments have occurred, with a consensus rating of "Moderate Buy".

The demand for Relmada Therapeutics' products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by the successful progression of drug candidates through clinical trials, regulatory approvals, disease prevalence, and market adoption upon commercialization.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for oncology and central nervous system disorders. The company operates within the Medical sector, specifically in the Biotechnology and Pharmaceutical Products industries, with a focus on Drug Discovery. Its primary product candidates include NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel, currently in Phase 2 clinical trials and advancing into Phase 3; Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready; and REL-P11, a modified-release formulation of psilocybin that has completed a Phase 1 safety study.

Relmada Therapeutics operates in the United States, with its headquarters in Coral Gables, Florida. Clinical trials for NDV-01 have also been conducted in Israel.

Relmada Therapeutics' brand reputation has been influenced by its clinical development progress and financial activities. Positive Phase 2 interim data for NDV-01 and successful $160 million PIPE financing indicate positive momentum. Analyst consensus rates the company as a "Moderate Buy," with an average rating score of 2.71.

Relmada Therapeutics has 80 institutional owners and shareholders holding a total of 50,846,664 shares. Major institutional owners include Janus Henderson Group Plc, Squadron Capital Management LLC, and Adage Capital Partners Gp, L.l.c., among others.